Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Stuart Goldberg, MD, Mauricette Michallet, MD PhD, Rudiger Hehlmann, MD, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Aimee Foreman, Brian Calimlim, Ron Paquette, MD, Bengt Simonsson, MD, Carlo Gambacorti, MD PhD, Jorge E. Cortes, MD, Aleksandra Zagorska, Yuanxin Rong, Michael J. Mauro, MD

Blood (2016) 128 (22): 937.

https://doi.org/10.1182/blood.V128.22.937.937

Published: 2016

Journal Articles

Bosutinib is a Substrate of the ABC Efflux Transporter P-Glycoprotein.

Pietro Perini, MS, Sara Redaelli, PhD, Rocco Piazza, MD, Michela Viltadi, MS, Frank Boschelli, PhD, Carlo Gambacorti, MD

Blood (2009) 114 (22): 3763.

https://doi.org/10.1182/blood.V114.22.3763.3763

Published: 2009

Journal Articles

BCR and BCR/ABL Regulation during Myeloid Differentiation in Healthy Donors and in Chronic Phase/Blast Crisis CML Patients

Manuela Marega, MS, Rocco Piazza, MD, Iris Meneghetti, Sara Redaelli, MS, Angela Mogavero, Carlo Gambacorti, MD

Blood (2008) 112 (11): 3204.

https://doi.org/10.1182/blood.V112.11.3204.3204

Published: 2008

Journal Articles

Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants

Sara Redaelli, MS, Rocco Piazza, MD, Roberta Rostagno, Marianna Sassone, MD, Vera Magistroni, PhD, Pietro Perini, MS, Manuela Marega, MS, Frank Boschelli, PhD, Carlo Gambacorti, MD

Blood (2008) 112 (11): 3220.

https://doi.org/10.1182/blood.V112.11.3220.3220

Published: 2008

Journal Articles

Dasatinib Inhibits Multiple Myeloma Growth by Blocking PDGF-Rb and c-Src Activity in Patient-Derived Tumor and Endothelial Cells.

Addolorata M.L. Coluccia, PhD, Teresa Cirulli, Paola Neri, Franco Dammacco, MD, Pierfrancesco Tassone, PhD, Carlo Gambacorti, MD, Angelo Vacca, MD

Blood (2007) 110 (11): 550.

https://doi.org/10.1182/blood.V110.11.550.550

Published: 2007

Journal Articles

A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.

Jorge Cortes, MD, Hagop M. Kantarjian, MD, Michele Baccarani, MD, Tim H. Brummendorf, MD, Delong Liu, MD, Gert Ossenkoppele, MD, Angela D.G. Volkert, BA, Becker Hewes, MD, Laurence Moore, MD, PhD, Charles Zacharchuk, MD, PhD, Carlo Gambacorti, MD

Blood (2006) 108 (11): 168.

https://doi.org/10.1182/blood.V108.11.168.168

Published: 2006

Journal Articles

Higher Prevalence of Prior Prostate Cancer in Patients Diagnosed with Chronic Myelogenous Leukemia.

Sarit Assouline, MD, MSc, J.A. Delaney, MSc, Carlo Gambacorti, MD, Samy Suissa, PhD

Blood (2006) 108 (11): 4795.

https://doi.org/10.1182/blood.V108.11.4795.4795

Published: 2006

Journal Articles

Bim Promoter Is Highly Methylated in Malignant Lymphoid Cell Lines, Leading to Downregulation of Bim Expression and Protection from Apoptosis.

Rocco G. Piazza, MD, PhD, Vera Magistroni, Federica Andreoni, Anna Franceschino, MD, Carlo Gambacorti, MD

Blood (2005) 106 (11): 2625.

https://doi.org/10.1182/blood.V106.11.2625.2625

Published: 2005

NARROW

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Bosutinib is a Substrate of the ABC Efflux Transporter P-Glycoprotein.

BCR and BCR/ABL Regulation during Myeloid Differentiation in Healthy Donors and in Chronic Phase/Blast Crisis CML Patients

Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants

Dasatinib Inhibits Multiple Myeloma Growth by Blocking PDGF-Rb and c-Src Activity in Patient-Derived Tumor and Endothelial Cells.

A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.

Higher Prevalence of Prior Prostate Cancer in Patients Diagnosed with Chronic Myelogenous Leukemia.

Bim Promoter Is Highly Methylated in Malignant Lymphoid Cell Lines, Leading to Downregulation of Bim Expression and Protection from Apoptosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only